Skip to main content
Data in Brief logoLink to Data in Brief
. 2020 Feb 21;29:105313. doi: 10.1016/j.dib.2020.105313

HPLC, quantitative NMR and HRMS spectroscopic data of nusbiarylins as a new class of antimicrobial agents

Yangyi Qiu 1, Cong Ma 1,
PMCID: PMC7056622  PMID: 32154348

Abstract

Bacterial transcription is a valid but underutilized target for antimicrobial agent discovery [1]. Nusbiarylins are the first-in-class bacterial ribosomal RNA synthesis inhibitors that possess potent activity against various types of multidrug-resistant bacteria with a novel mode of action by targeting the interaction of bacterial transcription factors NusB and NusE [2]. To facilitate the characterization of nusbiarylin derivatives produced by other researchers, high-performance liquid chromatography (HPLC) profiles, quantitative nuclear magnetic resonance (qNMR) and high-resolution mass spectrometry (HRMS) spectroscopic data were presented for the quick determination of purity and characterization of 95 nusbiarylin compounds. The data presented in this article supplement the 1H and 13C NMR data provided previously [3,4], and assist the reproduction of nusbiarylins for chemical, biological and drug discovery research.

Keywords: Inhibitor, Bacterial transcription, NusB-NusE interaction, HPLC, qNMR, HRMS


Specifications Table

Subject Chemistry
Specific subject area Organic chemistry
Analytical chemistry
Type of data Table
Figure
How data were acquired Agilent 1100 series and 1260 infinity system
Bruker ultrashield™ NMR spectrometer 600 MHz
Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS spectrometer
Data format Raw (as supplementary file)
Analyzed
Parameters for data collection The purified compounds were subjected to HPLC and qNMR analysis. The mobile phase for HPLC analysis were acetonitrile and water. The ratio was specified in the “Experimental Design, Materials, and Methods” section. The flow rate was set as 1.000 mL/min. Compounds were dissolved in d-DMSO prior to qNMR analysis. The parameters for qNMR analysis were adjusted according to the literature [5].
Description of data collection HPLC profiles of 95 novel compounds were recorded on and exported from an Agilent 1100 series and 1260 infinity system. Area% and RetTime stands for purity and retention time, respectively. qNMR spectra data of 95 novel compounds were recorded on and exported form a Bruker ultrashield™ NMR spectroscope 600 MHz spectrometer using standard Bruker pulse programs. Chemical shifts were shown as δ-values.
Positive- and negative-ion HRESI-TOF-MS of 95 novel compounds were recorded on and exported from an Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS spectrometer.
Data source location Department of Applied Biology and Chemical Technology, the Hong Kong Polytechnic University, Hong Kong SAR
Data accessibility Data are available with the article
Value of the Data
  • Nusbiarylins are the first-in-class bacterial ribosomal RNA synthesis inhibitors that possess potent activity against various types of multidrug-resistant bacteria with a novel mode of action

  • Spectral data of nusbiarylins are useful for elucidating their purity

  • The HPLC profiles, qNMR and HRMS spectroscopic data are of 95 unreported compounds and could be useful for the characterization by other researchers

1. Data

Bacterial transcription is a valid but underutilized target for antimicrobial agent discovery [1]. NusB and NusE are bacteria-specific transcription factors essential for cell viability [1,2]. Inhibitors of the NusB-NusE interaction were discovered and named nusbiarylins. The name was derived from the target protein NusB and their biaryl structure [[2], [3], [4]]. The dataset contains high-performance liquid chromatography (HPLC) profiles of 90 compounds, quantitative nuclear magnetic resonance (qNMR) spectroscopic data of 5 compounds and high-resolution mass spectrometry (HRMS) profiles of all 95 compounds [3,4]. The data file (HPLC, qNMR and HRMS spectra) is available publicly within this data article as a supplementary file. The compound structures were presented in Table 1, purities in Table 2 and HRMS data in Table 3. The testing methods and parameters of different compounds by HPLC, HRMS and qNMR were also described.

Table 1.

Chemical structures of 95 nusbiarylin compounds as NusB-NusE inhibitors.

1.

1.

Table 2.

Data on purities by HPLC or qNMR and retention time (HPLC) of nusbiarylin compounds.

Compound Purity/% Retention time/min
1 99.9 6.51
2 99.0 11.23
3 99.8 9.06
4 98.2 9.35
5 98.0 9.47
6 100.0 9.32
7 99.5 9.90
8 99.8 10.12
9 99.9 10.12
10 99.4 12.10
11 100.0 12.35
12 99.2 12.50
13 96.0 5.66
14 97.8 6.59
15 96.1 6.35
16 98.5 10.17
17 96.6 10.51
18 95.5 10.50
19 97.8 7.80
20 98.7 9.04
21 99.9 9.02
22 98.4 qNMR
23 97.2 9.15
24 98.9 qNMR
25 100.0 10.09
26 98.3 10.55
27 97.3 qNMR
28 97.4 8.98
29 97.0 9.76
30 95.5 9.69
31 95.3 5.95
32 97.2 5.77
33 91.0 qNMR
34 99.2 9.21
35 100.0 7.86
36 99.4 6.48
37 99.7 6.81
38 97.7 6.70
39 99.8 6.58
40 99.8 7.14
41 100.0 7.11
42 98.0 7.17
43 99.4 8.67
44 98.6 8.92
45 99.6 9.15
46 96.3 5.25
47 99.3 4.70
48 99.5 7.45
49 99.3 7.35
50 99.7 7.32
51 98.9 6.82
52 99.7 6.27
53 97.6 6.05
54 99.6 7.44
55 98.0 6.21
56 99.6 5.80
57 99.4 7.84
58 99.0 7.72
59 97.6 7.68
60 98.7 6.79
61 99.4 4.33
62 98.9 12.92
63 98.1 9.85
64 97.1 9.87
65 99.4 9.02
66 97.7 8.46
67 97.6 9.46
68 99.8 9.68
69 99.9 9.32
70 99.8 9.62
71 97.2 9.73
72 98.0 8.46
73 95.1 7.03
74 97.7 qNMR
75 99.4 12.08
76 98.3 6.52
77 99.2 6.98
78 99.1 6.33
79 99.7 6.19
80 98.7 6.54
81 99.6 6.94
82 99.4 8.25
83 99.9 8.43
84 99.6 7.23
85 99.5 8.45
86 99.7 7.93
87 100.0 8.96
88 95.5 8.02
89 97.2 8.05
90 97.4 7.91
91 96.8 7.20
92 97.6 7.79
93 97.7 7.76
94 98.9 17.74
95 99.7 7.46

Table 3.

HRMS data of nusbiarylin compounds.

Compound Ion formula m/z (calculated) m/z (found)
1 C13H15N2O3 [M − H]- 247.1088 247.1089
2 C17H11N2O3 [M − H]- 291.0775 291.0773
3 C13H9N2O3 [M − H]- 241.0619 241.0620
4 C13H8FN2O3 [M − H]- 259.0524 259.0523
5 C13H8FN2O3 [M − H]- 259.0524 259.0528
6 C13H8FN2O3 [M − H]- 259.0524 259.0522
7 C14H11N2O3 [M − H]- 255.0775 255.0771
8 C14H11N2O3 [M − H]- 255.0775 255.0772
9 C14H11N2O3 [M − H]- 255.0775 255.0772
10 C17H17N2O3 [M − H]- 297.1245 297.1247
11 C17H17N2O3 [M − H]- 297.1245 297.1242
12 C17H17N2O3 [M − H]- 297.1245 297.1243
13 C13H9N2O4 [M − H]- 257.0568 257.0565
14 C13H9N2O4 [M − H]- 257.0568 257.0568
15 C13H9N2O4 [M − H]- 257.0568 257.0567
16 C13H8ClN2O3 [M − H]- 275.0229 275.0227
17 C13H8ClN2O3 [M − H]- 275.0229 275.0226
18 C13H8ClN2O3 [M − H]- 275.0229 275.0226
19 C14H11N2O4 [M − H]- 271.0724 271.0719
20 C14H11N2O4 [M − H]- 271.0724 271.0721
21 C14H11N2O4 [M − H]- 271.0724 271.0727
22 C15H11N2O5 [M − H]- 299.0673 299.0672
23 C15H11N2O5 [M − H]- 299.0673 299.0669
24 C15H11N2O5 [M − H]- 299.0673 299.0672
25 C14H8F3N2O3 [M − H]- 309.0493 309.0492
26 C14H8F3N2O3 [M − H]- 309.0493 309.0491
27 C14H8F3N2O3 [M − H]- 309.0493 309.0490
28 C15H9N2O3 [M − H]- 265.0619 265.0618
29 C15H9N2O3 [M − H]- 265.0619 265.0620
30 C15H9N2O3 [M − H]- 265.0619 265.0615
31 C14H11N2O4 [M − H]- 271.0724 271.0721
32 C14H11N2O4 [M − H]- 271.0724 271.0722
33 C14H9N2O5 [M − H]- 285.0517 285.0513
34 C13H17N2O3 [M − H]- 249.1245 249.1245
35 C17H13N2O3 [M − H]- 293.0932 293.0929
36 C13H11N2O3 [M − H]- 243.0775 243.0775
37 C13H10FN2O3 [M − H]- 261.0681 261.0683
38 C13H10FN2O3 [M − H]- 261.0681 261.0679
39 C13H10FN2O3 [M − H]- 261.0681 261.0682
40 C14H13N2O3 [M − H]- 257.0932 257.0928
41 C14H13N2O3 [M − H]- 257.0932 257.0928
42 C14H13N2O3 [M − H]- 257.0932 257.0927
43 C17H19N2O3 [M − H]- 299.1401 299.1401
44 C17H19N2O3 [M − H]- 299.1401 299.1399
45 C17H19N2O3 [M − H]- 299.1401 299.1404
46 C13H11N2O4 [M − H]- 259.0724 259.0723
47 C13H11N2O4 [M − H]- 259.0724 259.0723
48 C13H10ClN2O3 [M − H]- 277.0385 277.0384
49 C13H10ClN2O3 [M − H]- 277.0385 277.0387
50 C13H10ClN2O3 [M − H]- 277.0385 277.0386
51 C14H13N2O4 [M − H]- 273.0881 273.0878
52 C14H13N2O4 [M − H]- 273.0881 273.0876
53 C14H13N2O4 [M − H]- 273.0881 273.0881
54 C15H13N2O5 [M − H]- 301.0830 301.0833
55 C15H13N2O5 [M − H]- 301.0830 301.0831
56 C15H13N2O5 [M − H]- 301.0830 301.0826
57 C14H10F3N2O3 [M − H]- 311.0649 311.0651
58 C14H10F3N2O3 [M − H]- 311.0649 311.0650
59 C14H10F3N2O3 [M − H]- 311.0649 311.0654
60 C15H11N2O3 [M − H]- 267.0775 267.0773
61 C14H13N2O4 [M − H]- 273.0881 273.0879
62 C14H11N2O5 [M − H]- 287.0673 287.0673
63 C17H12NO3 [M − H]- 278.0823 278.0822
64 C15H9FNO [M − H]- 238.0674 238.0672
65 C16H9N2O [M − H]- 245.0720 245.0719
66 C17H11N2O [M − H]- 259.0877 259.0876
67 C16H12NO2 [M − H]- 258.0874 258.0875
68 C15H10NO [M − H]- 220.0768 220.0772
69 C15H11N2O2 [M + H]+ 251.0815 251.0818
70 C16H13N2O3 [M + H]+ 281.0921 281.0922
71 C15H9N2O3 [M − H]- 265.0619 265.0620
72 C15H9N2O3 [M − H]- 265.0619 265.0616
73 C15H9N2O3 [M − H]- 265.0619 265.0621
74 C15H8BrN2O3 [M − H]- 342.9724 342.9727
75 C15H8Cl2NO [M − H]- 287.9988 287.9987
76 C17H14NO3 [M − H]- 280.0979 280.0974
77 C15H11FNO [M − H]- 240.0830 240.0829
78 C16H11N2O [M − H]- 247.0877 247.0876
79 C17H13N2O [M − H]- 261.1033 261.1032
80 C16H14NO2 [M − H]- 252.1030 252.1023
81 C15H12NO [M − H]- 222.0924 222.0923
82 C15H13N2O2 [M + H]+ 253.0972 253.0974
83 C16H15N2O3 [M + H]+ 283.1077 283.1080
84 C15H11N2O3 [M − H]- 267.0775 267.0773
85 C15H11N2O3 [M − H]- 267.0775 267.0770
86 C15H10BrN2O3 [M − H]- 344.9880 344.9878
87 C15H10Cl2NO [M − H]- 290.0145 290.0141
88 C14H10NO3 [M − H]- 240.0666 240.0662
89 C15H12NO4 [M − H]- 270.0772 270.0769
90 C15H12NO4 [M − H]- 270.0772 270.0771
91 C15H9N2O3 [M − H]- 265.0619 265.0617
92 C16H12NO5 [M − H]- 298.0721 298.0717
93 C16H12NO5 [M − H]- 298.0721 298.0719
94 C15H9N2O4 [M − H]- 281.0568 281.0571
95 C13H8NO4 [M − H]- 242.0459 242.0454

2. Experimental design, materials, and methods

2.1. HPLC analysis

2.1.1. Sample preparation and HPLC analysis

Approximately 0.1 mg of derivatives were dissolved in 1 mL of HPLC grade acetonitrile. 20 μL of supernatant was manually loaded onto the sample loop. The analysis was carried out on Agilent 1100 series and 1260 infinity system consisting of G1322A degasser, G1311A quat pump and G1365B multi-wavelength detector (MWD). The chromatographic parameters were set as follows:

  • Mobile phase: Mobile phase A: MeCN, Mobile phase B: H2O

  • Detector: MWD at 254 nm

  • Column: Agilent ZORBAX Eclipse Plus C18 (4.6 × 100 mm, 5 μm)

  • Flow rate: 1.000 mL/min

  • Gradient programme:

  • For compound 29, 60, 76, 87, 88

t/min Mobile phase A Mobile phase B
0 30% 70%
2 40% 60%
3 50% 50%
9 80% 20%
14 90% 10%
15 100% 0%
16.5 80% 20%
17 60% 40%
20 30% 70%
  • For compound 34, 62, 94

t/min Mobile phase A Mobile phase B
0 10% 90%
8 30% 70%
14 50% 50%
24 100% 0%
25 80% 20%
27 40% 60%
28 10% 90%
  • For the remaining compounds except compounds 22, 24, 27, 33, 74

t/min Mobile phase A Mobile phase B
0 30% 70%
2 40% 60%
3 50% 50%
13 100% 0%
16.5 30% 70%

2.1.2. Data processing

The automated integration software ChemStation for LC systems B.03.02 [341] was used to acquire the area under the curve (mAU). The obtained spectra were then exported as images.

2.2. qNMR analysis

2.2.1. Sample preparation and qNMR analysis

Samples were weighed into 5 mm standard NMR tubes using OHAUS® analytical plus balance, followed by addition of 500 μL of DMSO-d6 and indicated volume of internal reference 1,3,5-trioxane (99.66% pure, 9.98 mg/mL in DMSO-d6) purchased from Dieckmann (Hong Kong) Chemical Industry co., LTD. qNMR analysis were carried out via Bruker ultrashield™ NMR spectrometer 600 MHz. NMR instrument controlled parameters were adjusted as follows [5]:

  • Sample Temperature: 25 °C (298 K, regulated ± 0.1 K)

  • Data Points (acquired): 64 K

  • Zero-Filling (SI or FN): to 256 K

  • Dummy Scans: 4

  • Relaxation delay (D1): 60 s

  • Scans (NS or NT): 16

2.2.2. Data processing

The software Bruker topspin 3.2 was used to acquire the integrals of the signals of sample and internal reference. The normalized integrals values per proton equivalent by dividing each integral by the corresponding number of protons were calculated, so as the integral of the analyte (Intt and IntIC) as the average of all normalized integrals. The total number of protons (nt and nIC) was set to one [5]. Purities was then calculated according to the equation as below:

P[%]=nICInttMWtmICntIntICMWICmsPIC

where: P = purity of tested compound

  • mIC = weight of the internal calibrant (IC)

  • ms = weight of the sample

  • IntIC = integral of the IC resonance signal being used for quantification

  • Intt = integral of the target analyte (t) resonance signal being used for quantification

  • nIC = number of protons that give rise to IntIC

  • nt = number of protons of the target analyte that give rise to Intt

  • MWIC = molecular weight of the internal calibrant

  • MWt = molecular weight of the target analyte

  • PIC = purity of the internal calibrant, as percent value

2.3. HRMS analysis for all compounds

2.3.1. Sample preparation and HRMS analysis

Approximately 0.1 mg of derivatives were dissolved in 1 mL of HPLC grade acetonitrile. After sonication and filtration via 0.22 μm PTFE syringe filter, 10 μL of the upper layer was injected using an autosampler onto Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS spectrometer. The spectrometer was calibrated before each chromatographic run for optimal mass accuracy. The mobile phase gradient was 100% acetonitrile, at a flow rate of 0.5 ml/min. The mass spectra were acquired in positive- or negative-ion mode with source temperature at 300 °C. Ion spray voltage and fragmentor voltage were adjusted to 3.5 kV and 175 V, respectively. The range of mass detected was between 100 m/z and 1000 m/z.

2.3.2. Data processing

HRMS profiles were acquired and processed using MassHunter B.07 software. The obtained spectra were then exported as images.

Acknowledgments

We thank the funding support from the Research Grants Council of the Hong Kong Special Administrative Region, China (PolyU 251000/17M and 151000/19M), Hong Kong Polytechnic University internal grants (G-YBYY, 1-ZVPS and large equipment fund) and State Key Laboratory of Chemical Biology and Drug Discovery.

Footnotes

Appendix A

Supplementary data related to this article can be found at https://doi.org/10.1016/j.dib.2020.105313.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

The following are the supplementary data related to this article:

Multimedia component 1
mmc1.pdf (3.4MB, pdf)
Multimedia component 2
mmc2.xml (377B, xml)

References

  • 1.Ma C., Yang X., Lewis P.J. Bacterial transcription as a target for antibacterial drug development. Microbiol. Mol. Biol. Rev. 2016;80:139–160. doi: 10.1128/MMBR.00055-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Yang X., Luo M.J., Yeung A.C.M., Lewis P.J., Chan P.K.S., Ip M., Ma C. First-in-class inhibitor of ribosomal RNA synthesis with antimicrobial activity against Staphylococcus aureus. Biochemistry. 2017;56:5049–5052. doi: 10.1021/acs.biochem.7b00349. [DOI] [PubMed] [Google Scholar]
  • 3.Qiu Y., Chan S.T., Lin L., Shek T.L., Tsang T.F., Barua N., Zhang Y., Ip M., Chan P.K.-S., Blanchard N., Hanquet G., Zuo Z., Yang X., Ma C. Design, synthesis and biological evaluation of antimicrobial diarylimine and–amine compounds targeting the interaction between the bacterial NusB and NusE proteins. Eur. J. Med. Chem. 2019;178:214–231. doi: 10.1016/j.ejmech.2019.05.090. [DOI] [PubMed] [Google Scholar]
  • 4.Qiu Y., Chan S.T., Lin L., Shek T.L., Tsang T.F., Zhang Y., Ip M., Chan P.K.-S., Blanchard N., Hanquet G., Zuo Z., Yang X., Ma C. Nusbiarylins, a new class of antimicrobial agents: rational design of bacterial transcription inhibitors targeting the interaction between the NusB and NusE proteins. Bioorg. Chem. 2019;92:103203. doi: 10.1016/j.bioorg.2019.103203. [DOI] [PubMed] [Google Scholar]
  • 5.Pauli G.F., Chen S.-N., Simmler C., Lankin D.C., Gödecke T., Jaki B.U., Friesen B.J., McAlpine J.B., Napolitano J.G. Importance of purity evaluation and the potential of quantitative 1H NMR as a purity assay. J. Med. Chem. 2014;57:9220–9231. doi: 10.1021/jm500734a. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.pdf (3.4MB, pdf)
Multimedia component 2
mmc2.xml (377B, xml)

Articles from Data in Brief are provided here courtesy of Elsevier

RESOURCES